KPV vs Thymosin Alpha-1

KPV: Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone. Typical dose 200-500 mcg. Thymosin Alpha-1: Thymic peptide with broad immunomodulatory activity, approved in over 35 countries. Typical dose 1000-1600 mcg. Both fall under the Healing & Recovery and Immune categories.

Stacking KPV with Thymosin Alpha-1 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

KPV is typically dosed: Once or twice daily (oral or SubQ) for Gut inflammation support; Once daily (SubQ) for Systemic anti-inflammatory. Thymosin Alpha-1 is typically dosed: Twice weekly (SubQ) for Immune modulation; Twice weekly for Hepatitis treatment (clinical protocol); Daily for initial phase, then twice weekly for Acute immune support.

KPV: Not FDA approved for human use. Thymosin Alpha-1: Not FDA approved. Granted orphan drug designation for hepatocellular carcinoma and hepatitis B. Multiple clinical trials conducted but no NDA submitted.